Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2005

View Archived Issues

Maruho takes over Farom marketing after Yamanouchi ends agreement

Phase III Tysabri study in MS meets two-year endpoint

Enrollment completed in phase II study of avanafil

Voyager completes phase II Alzheimer's study

HIF-1alpha inhibitor blocks proliferation of various tumor cells in normoxic and hypoxic conditions

Inhibition of IL-6 signaling might be a new approach for allergic asthma treatment

Preclinical data on broad-spectrum antitumor agent BMS-250749

Orally efficacious MCH-1 receptor antagonist tested for the treatment of obesity

Ki-8751: Novel antitumor compound from Kirin

Aastrom expands U.S. Tissue Repair Cells study

SBIR grant supports Adenosine Therapeutics' Parkinson's efforts

Long-lasting responses seen in mycosis fungoides patients receiving HuMax-CD4

First phase I safety study for ASM-8 for asthma

TQ-1017 receives orphan drug status for HIV-associated neuropathy

Pentrys prostate cancer study nearing completion of enrollment

KM-668 enters preclinical testing as radioprotectant

Amitriptyline studied for painful bladder syndrome and interstitial cystitis

Duska Therapeutics updates recent developments

Spotlight on N-palmitoylethanolamide: multiple potential therapeutic effects

New data on the benefits of AMD-3100 in stem cell transplantation for cancer patients

Therapeutic benefits of oxypurinol in congestive heart failure

A 2% green tea extract shows promise in the treatment of papulopustular rosacea

In vitro data support the broad-spectrum antifungal activity of R-126638

Novel 5-HT1A receptor antagonists claimed by Wyeth for depression and anxiety

Merck identifies new mitotic kinesin inhibitors for use in cancer therapy

Salvat discloses new PPAR receptor modulators

Novel anti-HCV agents claimed by the Italian researchers

Novel DPP-IV inhibitors for type 2 diabetes imparted by Fujisawa

Japan Science and Technology develops fusion protein for atherosclerosis and cancer

New antibacterial monoclonal antibodies reported by Japan Science and Technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...